FDA Approves Setmelanotide for Obesity in Bardet-Biedl Syndrome

The FDA cleared setmelanotide (Imcivree) for people age 6 and older with obesity due to a rare genetic disorder, Bardet-Biedl Syndrome, adding to its approval for other rare diseases causing obesity.
FDA Approvals

source https://www.medscape.com/viewarticle/975797?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost